BioAge Labs Doses First Participant in QUELL-CV Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
BioAge Labs announced that the first participant has been dosed in QUELL-CV, a Phase 2 proof-of-concept clinical trial of BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor. BGE-102 is being developed as a once-daily oral therapy, with cardiovascular risk reduction as the lead indication.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIOA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIOA
Wall Street analysts forecast BIOA stock price to rise
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 20.490
Low
15.00
Averages
37.00
High
73.00
Current: 20.490
Low
15.00
Averages
37.00
High
73.00
About BIOA
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioArctic AB Issues Stock Information
- Stock Issuance: BioArctic AB issued 5,000 Class B shares in May 2026 to fulfill obligations under the 2019/2028 stock option program, demonstrating the company's ongoing commitment to shareholder incentive mechanisms.
- Total Shares Update: As of May 29, 2026, BioArctic AB has a total of 88,724,485 shares, including 74,324,489 listed Class B shares and 14,399,996 unlisted Class A shares, reflecting the company's stability in the capital market.
- Voting Rights Structure: Class A shares carry ten votes per share while Class B shares have one vote each, resulting in a total voting power of 218,324,449 votes, which may influence shareholder decisions and corporate governance.
- Market Compliance Information: This disclosure complies with EU Market Abuse Regulation requirements, indicating BioArctic AB's emphasis on transparency and compliance, which helps to enhance investor confidence.
See More
BioArctic AB Issues 5,000 Class B Shares for Stock Option Program
- Share Issuance Details: BioArctic AB issued 5,000 Class B shares in May 2026 to fulfill obligations under the 2019/2028 stock option program, highlighting the company's commitment to employee incentive mechanisms aimed at enhancing motivation and loyalty.
- Total Shares Update: As of May 29, 2026, BioArctic AB has a total of 88,724,485 shares, including 74,324,489 listed Class B shares and 14,399,996 unlisted Class A shares, reflecting the company's stability and transparency in the capital market.
- Voting Rights Structure: Class A shares carry ten votes per share, while Class B shares have one vote each, resulting in a total voting power of 218,324,449 votes, which helps maintain the control of founding shareholders and ensures strategic consistency in company direction.
- Regulatory Compliance Information: This disclosure complies with EU Market Abuse Regulation, demonstrating BioArctic AB's commitment to transparency and compliance, which can enhance investor confidence and improve the company's public image.
See More
BioArctic AB Annual General Meeting Resolutions
- AGM Resolutions: At the Annual General Meeting on May 28, 2026, BioArctic AB adopted its financial statements and declared a dividend of SEK 2 per share with a record date of June 1, 2026, which is expected to bolster shareholder confidence and attract further investment.
- Board Member Elections: The meeting re-elected Eugen Steiner as chairperson and appointed Philip Scheltens and Linda Nilsson as new board members, ensuring a blend of continuity and fresh perspectives that will aid in executing the company's strategic initiatives and innovations.
- Incentive Program Launch: The company introduced a three-year incentive program allowing for up to 235,000 performance-based share units to be awarded, aimed at motivating employees to enhance performance and drive long-term growth and competitiveness in the market.
- Auditor Appointment: The meeting resolved to appoint PwC as the company's auditor, ensuring financial transparency and compliance, which is expected to enhance investor trust in the company's financial health.
See More
BioArctic AB Annual General Meeting Resolutions
- AGM Resolutions: BioArctic AB held its Annual General Meeting in Stockholm, adopting the income statement and balance sheet for FY 2025, and declaring a dividend of SEK 2 per share with a record date of June 1, 2026, which is expected to enhance shareholder confidence and improve the company's image.
- Board Member Elections: The meeting re-elected six board members including Eugen Steiner and appointed Philip Scheltens and Linda Nilsson, ensuring stability and continuity in corporate governance as all members serve until the next AGM.
- Incentive Program Launch: The company introduced a three-year incentive program allowing for up to 235,000 performance-based share units, designed to motivate employees to achieve a 30% total shareholder return, thereby driving long-term growth for the company.
- Auditor Appointment: The meeting resolved to appoint PwC as the company's auditor until the next AGM, ensuring financial transparency and compliance, which will help bolster investor trust in the company.
See More
Wall Street's Latest Rating Changes Overview
- Openlane Upgrade: JPMorgan upgraded Openlane from neutral to overweight and raised its December 2026 price target to $38, indicating that the online used car marketplace is experiencing robust growth and has potential for sustainable expansion over the coming years.
- Dollar General Downgrade: Deutsche Bank downgraded Dollar General from buy to hold, citing challenges in its customer base and the widening gap in the K-shaped economy, which may limit same-store sales upside, reflecting a cautious outlook on the company.
- Ecolab Upgrade: UBS upgraded Ecolab from neutral to buy and raised its price target to $325, demonstrating strong demand and positive performance expectations for the chemicals company amid a favorable market environment.
- FedEx Upgrade: JPMorgan upgraded FedEx from neutral to overweight, expressing optimism ahead of its upcoming earnings report, particularly regarding the separation of its freight business, which is seen as an attractive risk-reward opportunity.
See More
BioArctic and Eisai Release Leqembi Sales Forecast
- Future Sales Projection: Eisai's simulation indicates that Leqembi's sales are expected to reach approximately JPY 300 billion (around SEK 17.6 billion) for the fiscal year 2028, highlighting the drug's significant market potential and the prospect of substantial revenue growth for BioArctic.
- Global Market Approvals: Leqembi has been approved in 53 countries and is under regulatory review in 6 countries, demonstrating its broad acceptance in the global market and further solidifying BioArctic's leadership position in Alzheimer's disease treatment.
- Clinical Research Progress: Eisai's ongoing AHEAD 3-45 clinical study aims to evaluate the efficacy of lecanemab in early Alzheimer's disease patients, which is expected to provide crucial data for future market promotion and enhance BioArctic's competitive edge.
- Strategic Partnership: The long-term collaboration between BioArctic and Eisai since 2005 has positioned BioArctic advantageously in the development of Alzheimer's drugs, as it incurs no development costs and can earn milestone payments and royalties from global sales, ensuring financial stability.
See More
BioArctic AB Issues Stock Information
- Stock Issuance: BioArctic AB issued 5,000 Class B shares in May 2026 to fulfill obligations under the 2019/2028 stock option program, demonstrating the company's ongoing commitment to shareholder incentive mechanisms.
- Total Shares Update: As of May 29, 2026, BioArctic AB has a total of 88,724,485 shares, including 74,324,489 listed Class B shares and 14,399,996 unlisted Class A shares, reflecting the company's stability in the capital market.
- Voting Rights Structure: Class A shares carry ten votes per share while Class B shares have one vote each, resulting in a total voting power of 218,324,449 votes, which may influence shareholder decisions and corporate governance.
- Market Compliance Information: This disclosure complies with EU Market Abuse Regulation requirements, indicating BioArctic AB's emphasis on transparency and compliance, which helps to enhance investor confidence.
See More
BioArctic AB Issues 5,000 Class B Shares for Stock Option Program
- Share Issuance Details: BioArctic AB issued 5,000 Class B shares in May 2026 to fulfill obligations under the 2019/2028 stock option program, highlighting the company's commitment to employee incentive mechanisms aimed at enhancing motivation and loyalty.
- Total Shares Update: As of May 29, 2026, BioArctic AB has a total of 88,724,485 shares, including 74,324,489 listed Class B shares and 14,399,996 unlisted Class A shares, reflecting the company's stability and transparency in the capital market.
- Voting Rights Structure: Class A shares carry ten votes per share, while Class B shares have one vote each, resulting in a total voting power of 218,324,449 votes, which helps maintain the control of founding shareholders and ensures strategic consistency in company direction.
- Regulatory Compliance Information: This disclosure complies with EU Market Abuse Regulation, demonstrating BioArctic AB's commitment to transparency and compliance, which can enhance investor confidence and improve the company's public image.
See More
BioArctic AB Annual General Meeting Resolutions
- AGM Resolutions: At the Annual General Meeting on May 28, 2026, BioArctic AB adopted its financial statements and declared a dividend of SEK 2 per share with a record date of June 1, 2026, which is expected to bolster shareholder confidence and attract further investment.
- Board Member Elections: The meeting re-elected Eugen Steiner as chairperson and appointed Philip Scheltens and Linda Nilsson as new board members, ensuring a blend of continuity and fresh perspectives that will aid in executing the company's strategic initiatives and innovations.
- Incentive Program Launch: The company introduced a three-year incentive program allowing for up to 235,000 performance-based share units to be awarded, aimed at motivating employees to enhance performance and drive long-term growth and competitiveness in the market.
- Auditor Appointment: The meeting resolved to appoint PwC as the company's auditor, ensuring financial transparency and compliance, which is expected to enhance investor trust in the company's financial health.
See More
BioArctic AB Annual General Meeting Resolutions
- AGM Resolutions: BioArctic AB held its Annual General Meeting in Stockholm, adopting the income statement and balance sheet for FY 2025, and declaring a dividend of SEK 2 per share with a record date of June 1, 2026, which is expected to enhance shareholder confidence and improve the company's image.
- Board Member Elections: The meeting re-elected six board members including Eugen Steiner and appointed Philip Scheltens and Linda Nilsson, ensuring stability and continuity in corporate governance as all members serve until the next AGM.
- Incentive Program Launch: The company introduced a three-year incentive program allowing for up to 235,000 performance-based share units, designed to motivate employees to achieve a 30% total shareholder return, thereby driving long-term growth for the company.
- Auditor Appointment: The meeting resolved to appoint PwC as the company's auditor until the next AGM, ensuring financial transparency and compliance, which will help bolster investor trust in the company.
See More
Wall Street's Latest Rating Changes Overview
- Openlane Upgrade: JPMorgan upgraded Openlane from neutral to overweight and raised its December 2026 price target to $38, indicating that the online used car marketplace is experiencing robust growth and has potential for sustainable expansion over the coming years.
- Dollar General Downgrade: Deutsche Bank downgraded Dollar General from buy to hold, citing challenges in its customer base and the widening gap in the K-shaped economy, which may limit same-store sales upside, reflecting a cautious outlook on the company.
- Ecolab Upgrade: UBS upgraded Ecolab from neutral to buy and raised its price target to $325, demonstrating strong demand and positive performance expectations for the chemicals company amid a favorable market environment.
- FedEx Upgrade: JPMorgan upgraded FedEx from neutral to overweight, expressing optimism ahead of its upcoming earnings report, particularly regarding the separation of its freight business, which is seen as an attractive risk-reward opportunity.
See More
BioArctic and Eisai Release Leqembi Sales Forecast
- Future Sales Projection: Eisai's simulation indicates that Leqembi's sales are expected to reach approximately JPY 300 billion (around SEK 17.6 billion) for the fiscal year 2028, highlighting the drug's significant market potential and the prospect of substantial revenue growth for BioArctic.
- Global Market Approvals: Leqembi has been approved in 53 countries and is under regulatory review in 6 countries, demonstrating its broad acceptance in the global market and further solidifying BioArctic's leadership position in Alzheimer's disease treatment.
- Clinical Research Progress: Eisai's ongoing AHEAD 3-45 clinical study aims to evaluate the efficacy of lecanemab in early Alzheimer's disease patients, which is expected to provide crucial data for future market promotion and enhance BioArctic's competitive edge.
- Strategic Partnership: The long-term collaboration between BioArctic and Eisai since 2005 has positioned BioArctic advantageously in the development of Alzheimer's drugs, as it incurs no development costs and can earn milestone payments and royalties from global sales, ensuring financial stability.
See More
